Changes and Clinical Significance of Natural Killer-Like B Cells, Natural Killer Cells, and B Cells in Peripheral Blood of Patients with Hepatitis B Virus Infection
YANG Xiaofei,SHEN Huanjun,HUANG Gaobo,LIAN Jianqi,ZHANG Ye
DOI: https://doi.org/10.3969/j.issn.1001-5256.2022.07.008
2022-01-01
Abstract:ObjectiveTo investigate the changes of natural killer-like B (NKB) cells, natural killer (NK) cells, and B cells and their correlation with clinical indices in patients with hepatitis B virus (HBV) infection. MethodsA total of 15 patients with acute hepatitis B (AHB), 30 patients with chronic hepatitis B (CHB), 29 asymptomatic HBV carriers (ASCs), and 12 controls who attended Tangdu Hospital from January 2017 and December 2018 were enrolled. Peripheral blood samples were collected, and plasma and peripheral blood mononuclear cells (PBMCs) were isolated. ELISA was used to measure the plasma levels of interleukin-18 (IL-18) and interferon-γ (IFNγ), and enzyme-linked immunospot assay was used to measure the level of IFNγ secreted by HBV-specific CD8+ T cells; flow cytometry was used to measure the percentages of CD3-CD19+CD56+CD16+ NKB cells, different NK cell subsets (including CD3-CD19-CD56highCD16- NK cells, CD3-CD19-CD56+CD16+ NK cells, and CD3-CD19-CD56-CD16+ NK cells), and their correlation with viral replication and liver inflammation markers was analyzed. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; non-normally distributed continuous data were expressed as M(P25-P75), and the Kruskal-Wallis H test was used for comparison between multiple groups; the Pearson correlation test was used for correlation analysis. ResultsThere was a significant difference in the percentage of CD3-CD19+CD16+CD56+ NKB cells between the AHB patients, CHB patients, ASCs, and controls (F = 16.42, P ＜0.000 1), and the CHB patients had a significantly lower percentage of NKB cells than the AHB patients, ASCs, and controls (0.79%±0.13% vs 0.94%±0.15%/1.02%±0.12%/1.11%±0.27%, all P ＜0.001). There was a significant difference in plasma IL-18 level between the AHB patients, CHB patients, ASCs, and controls (F = 5.733, P = 0.001); the CHB patients had a significantly lower IL-18 level than the AHB patients and the controls (259.30±70.09 pg/mL vs 336.00±103.00 pg/mL and 319.30±64.80 pg/mL, both P ＜0.05), and ASCs had a significantly lower IL-18 level (258.60±59.82 pg/mL) than the AHB patients and the controls (both P ＜0.01), while there was no significant difference in plasma IL-18 level between the CHB patients and ASCs (P = 0.965). There were no significant differences in the percentage of CD3-CD19-CD56highCD16- NK cells, CD3-CD19-CD56+CD16+ NK cells, CD3-CD19-CD56-CD16+ NK cells, and B cells between the four groups (all P ＞0.05). The CHB patients had a significantly lower plasma IFNγ level than the AHB patients, ASCs, and controls (all P ＜0.01). The percentage of NKB cells and the level of IL-18 were not significantly correlated with HBV DNA quantification or alanine aminotransferase level (all P ＞0.05). In the CHB patients, the percentage of NKB cells was positively correlated with plasma IL-18 level (r = 0.432, P = 0.017) and the level of IFNγ secreted by HBV-specific CD8+ T cells (r =0493, P=0.006). ConclusionNKB cells and IL-18 might be involved in the chronicity of HBV infection and is associated with the natural history of chronic HBV infection.